医保药品目录动态调整的国际经验与启示  

International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog

作　　者：郑王彪 郑超 孙强[1,2] ZHENG Wangbiao;ZHENG Chao;SUN Qiang(Centre for Health Management and Policy Research,School of Public Health,Cheeloo College of Medicine,Shandong University,Jinan Shandong 250012,China;不详)

机构地区：[1]山东大学齐鲁医学院公共卫生学院卫生管理与政策研究中心,山东济南250012 [2]国家卫生健康委员会卫生经济与政策研究重点实验室(山东大学),山东济南250012

出　　处：《卫生经济研究》2023年第12期62-67,共6页

基　　金：山东省重点研发计划(软科学项目)“医保区域不平衡对城乡医保统筹和经济社会协调发展的影响研究”(2022RKY07003);中国博士后科学基金面上项目“新发展阶段医保政策解决因病致贫的长效机制研究”(2022M711941);山东省社会科学规划研究项目“中共社会医疗保障百年经验对健康强省建设的启示”(21CXSXJ11)。

摘　　要：英国、法国、韩国的医保药品目录调整经验显示,成熟的药品价值评估体系、分类管理机制和风险分担体系发挥了重要作用。我国可以适当借鉴国际经验,创新医保药品目录的动态调整机制,完善药品分类管理体系,依托独立的卫生技术评估机构开展全流程药物评估,以及建立多方参与的风险分担体系,满足人民群众多元化医疗保障需求。From the experience of adjusting the medical insurance drug catalog in the UK,France,and South Korea,it can be seen that mature drug value evaluation systems,classification management mechanisms,and risk sharing systems have played an important role.By appropriately drawing on international experience,we should innovate the dynamic adjustment mechanism of the medical insurance drug catalog,improve the drug classification management system,rely on independent health technology assessment institutions to conduct whole process drug evaluation,and establish a multi-party risk sharing system,in order to meet the diverse medical security demands of the people.

关 键 词：医保药品目录 动态调整机制 卫生技术评估 药品分类管理 

分 类 号：R197.1[医药卫生—卫生事业管理]